VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q71696785 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000226.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q71696785‏
024 ‎‡a 0000-0003-1460-3905‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q71696785‏
100 0 ‎‡a Laurence J. Cooper‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a Cooper LJ‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.‏
670 ‎‡a Author's A new approach to simultaneously quantify both TCR α- and β-chain diversity after adoptive immunotherapy‏
670 ‎‡a Author's Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma‏
670 ‎‡a Author's Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals‏
670 ‎‡a Author's Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity‏
670 ‎‡a Author's CARs on track in the clinic‏
670 ‎‡a Author's Complementarity, specificity and the nature of epitopes and paratopes in multivalent interactions.‏
670 ‎‡a Author's Cord-blood engraftment with ex vivo mesenchymal-cell coculture‏
670 ‎‡a Author's Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation‏
670 ‎‡a Author's Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation‏
670 ‎‡a Author's Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment‏
670 ‎‡a Author's Genetically modified artificial antigen-presenting cells‏
670 ‎‡a Author's Genetically modified artificial antigen-presenting cells (aAPC) for expansion of melanoma tumor infiltrating lymphocytes with optimal properties for adoptive cell therapy‏
670 ‎‡a Author's Immunotherapy targeting EBV-expressing lymphoproliferative diseases‏
670 ‎‡a Author's Lymphoid reconstruction and vaccines.‏
670 ‎‡a Author's Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector‏
670 ‎‡a Author's Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma‏
670 ‎‡a Author's Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells‏
670 ‎‡a Author's Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes‏
670 ‎‡a Author's Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial‏
670 ‎‡a Author's Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with 18F-FEAU‏
670 ‎‡a Author's Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome‏
670 ‎‡a Author's The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity‏
670 ‎‡a Author's The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation‏
670 ‎‡a Author's Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease‏
670 ‎‡a Author's Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism‏
909 ‎‡a (orcid) 0000000314603905‏ ‎‡9 1‏
919 ‎‡a tumormicroenvironmentderivedexosomespleiotropicallymodulatecancercellmetabolism‏ ‎‡A Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism‏ ‎‡9 1‏
919 ‎‡a 3partyumbilicalcordbloodderivedregulatorytcellspreventxenogenicgraftversushostdisease‏ ‎‡A Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease‏ ‎‡9 1‏
919 ‎‡a developmentofamyeloablativereducedtoxicityconditioningregimenforcordbloodtransplantation‏ ‎‡A The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation‏ ‎‡9 1‏
919 ‎‡a beneficialeffectsofagaspermeableflaskforexpansionoftumorinfiltratinglymphocytesasreflectedintheirmitochondrialfunctionandrespirationcapacity‏ ‎‡A The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity‏ ‎‡9 1‏
919 ‎‡a repetitivenoninvasivemonitoringofhsv1tkexpressingtcellsintravenouslyinfusedintononhumanprimatesusingpositronemissiontomographyandcomputedtomographywith18ffeau‏ ‎‡A Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with 18F-FEAU‏ ‎‡9 1‏
919 ‎‡a regulatableinterleukin12genetherapyinpatientswithrecurrenthighgradegliomaresultsofaphase1trial‏ ‎‡A Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial‏ ‎‡9 1‏
919 ‎‡a plasmacirculatingmicrornaprofilesareusefulforassessingprognosisinpatientswithcytogeneticallynormalmyelodysplasticsyndromes‏ ‎‡A Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes‏ ‎‡9 1‏
919 ‎‡a phase1studyofcordbloodderivednaturalkillercellscombinedwithautologousstemcelltransplantationinmultiplemyeloma‏ ‎‡A Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma‏ ‎‡9 1‏
919 ‎‡a phase1studyofchemokineandcytokinegenemodifiedautologousneuroblastomacellsfortreatmentofrelapsedrefractoryneuroblastomausinganadenoviralvector‏ ‎‡A Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector‏ ‎‡9 1‏
919 ‎‡a lymphoidreconstructionandvaccines‏ ‎‡A Lymphoid reconstruction and vaccines.‏ ‎‡9 1‏
919 ‎‡a immunotherapytargetingebvexpressinglymphoproliferativediseases‏ ‎‡A Immunotherapy targeting EBV-expressing lymphoproliferative diseases‏ ‎‡9 1‏
919 ‎‡a geneticallymodifiedartificialantigenpresentingcellsaapcforexpansionofmelanomatumorinfiltratinglymphocyteswithoptimalpropertiesforadoptivecelltherapy‏ ‎‡A Genetically modified artificial antigen-presenting cells (aAPC) for expansion of melanoma tumor infiltrating lymphocytes with optimal properties for adoptive cell therapy‏ ‎‡9 1‏
919 ‎‡a geneticallymodifiedartificialantigenpresentingcells‏ ‎‡A Genetically modified artificial antigen-presenting cells‏ ‎‡9 1‏
919 ‎‡a fucosylationwithfucosyltransferase6orfucosyltransferase7improvescordbloodengraftment‏ ‎‡A Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment‏ ‎‡9 1‏
919 ‎‡a enforcedfucosylationofcordbloodhematopoieticcellsacceleratesneutrophilandplateletengraftmentaftertransplantation‏ ‎‡A Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation‏ ‎‡9 1‏
919 ‎‡a derivationofhumantlymphocytesfromcordbloodandperipheralbloodwithantiviralandantileukemicspecificityfromasinglecultureasprotectionagainstinfectionandrelapseafterstemcelltransplantation‏ ‎‡A Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation‏ ‎‡9 1‏
919 ‎‡a cordbloodengraftmentwithexvivomesenchymalcellcoculture‏ ‎‡A Cord-blood engraftment with ex vivo mesenchymal-cell coculture‏ ‎‡9 1‏
919 ‎‡a phase1trialsusingsleepingbeautytogeneratecd19specificcartcells‏ ‎‡A Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells‏ ‎‡9 1‏
919 ‎‡a complementarityspecificityandthenatureofepitopesandparatopesinmultivalentinteractions‏ ‎‡A Complementarity, specificity and the nature of epitopes and paratopes in multivalent interactions.‏ ‎‡9 1‏
919 ‎‡a carsontrackintheclinic‏ ‎‡A CARs on track in the clinic‏ ‎‡9 1‏
919 ‎‡a aurorakinaseinhibitionsensitizesmelanomacellstotcellmediatedcytotoxicity‏ ‎‡A Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity‏ ‎‡9 1‏
919 ‎‡a telomeredysfunctiondrivesaberranthematopoieticdifferentiationandmyelodysplasticsyndrome‏ ‎‡A Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome‏ ‎‡9 1‏
919 ‎‡a altereddecamerandnonamerfromanhlaa0201restrictedepitopeofsurvivindifferentiallystimulatetcellresponsesindifferentindividuals‏ ‎‡A Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals‏ ‎‡9 1‏
919 ‎‡a activationandpropagationoftumorinfiltratinglymphocytesonclinicalgradedesignerartificialantigenpresentingcellsforadoptiveimmunotherapyofmelanoma‏ ‎‡A Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma‏ ‎‡9 1‏
919 ‎‡a newapproachtosimultaneouslyquantifybothtcrαandβchaindiversityafteradoptiveimmunotherapy‏ ‎‡A A new approach to simultaneously quantify both TCR α- and β-chain diversity after adoptive immunotherapy‏ ‎‡9 1‏
919 ‎‡a mir192egr1hoxb9regulatorynetworkcontrolstheangiogenicswitchincancer‏ ‎‡A A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.‏ ‎‡9 1‏
996 ‎‡2 NUKAT|n 2009081181‏
996 ‎‡2 LC|n 2007011821‏
996 ‎‡2 LC|n 98101416‏
996 ‎‡2 DNB|1161376267‏
996 ‎‡2 LC|no2020050697‏
996 ‎‡2 CAOONL|ncf10424575‏
996 ‎‡2 ISNI|0000000507167919‏
996 ‎‡2 BIBSYS|10007243‏
996 ‎‡2 ISNI|0000000114459021‏
996 ‎‡2 SZ|173428312‏
996 ‎‡2 LC|n 96030851‏
996 ‎‡2 ISNI|0000000023486016‏
996 ‎‡2 BIBSYS|15024671‏
996 ‎‡2 NTA|314570314‏
996 ‎‡2 NSK|000073525‏
996 ‎‡2 SUDOC|232625115‏
996 ‎‡2 BIBSYS|8049195‏
996 ‎‡2 LC|n 82021092‏
996 ‎‡2 LC|no 98103270‏
996 ‎‡2 LC|no2012072426‏
996 ‎‡2 LC|n 81135315‏
996 ‎‡2 ISNI|0000000036765583‏
996 ‎‡2 SUDOC|276755901‏
996 ‎‡2 NII|DA17660784‏
996 ‎‡2 NTA|138437629‏
996 ‎‡2 LC|n 2005018051‏
996 ‎‡2 BIBSYS|6013695‏
996 ‎‡2 ISNI|000000004300933X‏
996 ‎‡2 LC|n 2017189576‏
996 ‎‡2 LC|n 2014058657‏
996 ‎‡2 ISNI|0000000074134424‏
996 ‎‡2 NII|DA12404142‏
996 ‎‡2 DNB|173428312‏
996 ‎‡2 NKC|mub20201064604‏
996 ‎‡2 LC|n 78004591‏
996 ‎‡2 J9U|987009837828005171‏
996 ‎‡2 DNB|1327351471‏
996 ‎‡2 J9U|987007309689905171‏
996 ‎‡2 BNF|13745613‏
996 ‎‡2 LC|no2013036036‏
996 ‎‡2 ISNI|0000000021245497‏
996 ‎‡2 SUDOC|13597366X‏
996 ‎‡2 ISNI|0000000437081115‏
996 ‎‡2 LC|no2018106140‏
996 ‎‡2 LC|n 79023555‏
996 ‎‡2 CAOONL|ncf11321490‏
996 ‎‡2 DNB|1158415192‏
996 ‎‡2 RERO|A003133718‏
996 ‎‡2 LC|no2018041039‏
996 ‎‡2 LC|no2022068813‏
996 ‎‡2 J9U|987007363698705171‏
996 ‎‡2 LC|no2005033557‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏